SEC Tracker
Get the app

Immunovant IMVT

Immunovant FY 2023: net loss $211.0M; diluted EPS −$1.71

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Immunovant reported for the year ended Mar 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$211.0MAgainst −$156.7M in FY 202210-K income statement, on EDGAR
  2. Diluted EPS−$1.71Against −$1.43 in FY 202210-K income statement, on EDGAR
  3. Cash and cash equivalents$376.5M−24% from $493.8M in FY 202210-K balance sheet, on EDGAR
  4. Cash from operations−$188.2MAgainst −$106.1M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Immunovant files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Innoviva INVA public float $1.3B, Jun 30, 2025
  2. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  3. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025
  4. Travere Therapeutics TVTX public float $1.3B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.